<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Res Treat</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Res Treat</journal-id><journal-id journal-id-type="publisher-id">CRT</journal-id><journal-title-group><journal-title>Cancer Research and Treatment : Official Journal of Korean Cancer Association</journal-title></journal-title-group><issn pub-type="ppub">1598-2998</issn><issn pub-type="epub">2005-9256</issn><publisher><publisher-name>Korean Cancer Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26582396</article-id><article-id pub-id-type="pmc">4946357</article-id><article-id pub-id-type="doi">10.4143/crt.2015.264</article-id><article-id pub-id-type="publisher-id">crt-2015-264</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of <italic>Helicobacter pylori</italic> Eradication on Long-Term Survival after Distal Gastrectomy for Gastric Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Young-Il</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Soo-Jeong</given-names></name><degrees>MD</degrees><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jong Yeul</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Chan Gyoo</given-names></name><degrees>MD</degrees><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Kook</surname><given-names>Myeong-Cherl</given-names></name><degrees>MD</degrees><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Ryu</surname><given-names>Keun Won</given-names></name><degrees>MD</degrees><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Young-Woo</given-names></name><degrees>MD</degrees><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Il Ju</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref ref-type="corresp" rid="c1-crt-2015-264"/></contrib><aff id="af1-crt-2015-264">
Center for Gastric Cancer, National Cancer Center, <country>Korea</country></aff></contrib-group><author-notes><corresp id="c1-crt-2015-264">Correspondence: Il Ju Choi, MD, PhD&#x02003; Center for Gastric Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea&#x02003; Tel: 82-31-920-1629 Fax: 82-31-920-0069 E-mail: <email>cij1224@hanmail.net</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2015</year></pub-date><volume>48</volume><issue>3</issue><fpage>1020</fpage><lpage>1029</lpage><history><date date-type="received"><day>19</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>27</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 by the Korean Cancer Association</copyright-statement><copyright-year>2016</copyright-year><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>Negative <italic>Helicobacter pylori</italic> status has been identified as a poor prognostic factor for survival in gastric cancer (GC) patients who underwent surgery. The aim of this study was to examine the effect of <italic>H. pylori</italic> eradication on long-term outcomes after distal gastrectomy for GC.</p></sec><sec><title>Materials and Methods</title><p>We analyzed the survival of 169 distal GC patients enrolled in a prospective randomized trial evaluating histologic changes of gastric mucosa after <italic>H. pylori</italic> eradication in the remnant stomach. The outcomes measured were overall survival (OS) and GC recurrence rates.</p></sec><sec><title>Results</title><p>The median follow-up duration was 9.4 years. In the modified intention-to-treat analysis including patients who underwent <italic>H. pylori</italic> treatment (n=87) or placebo (n=82), 5-year OS rates were 98.9% in the treatment group and 91.5% in the placebo group, and Kaplan-Meier analysis showed no significant difference in OS (p=0.957) between groups. In multivariate analysis, no difference in overall mortality was observed between groups (adjusted hazard ratio [aHR] for <italic>H. pylori</italic> treatment, 0.75; p=0.495) or <italic>H. pylori</italic>-eradicated status (aHR for positive <italic>H. pylori</italic> status, 1.16; p=0.715), while old age, male sex, and advanced stage &#x02265; IIIa were independent risk factors. Six patients in the treatment group (6.9%) and seven patients in the placebo group (8.5%) had GC recurrences, and GC recurrence rates were not different according to <italic>H. pylori</italic> treatment (5-year GC recurrence rates, 4.6% in the treatment group vs. 8.5% in the placebo group; p=0.652).</p></sec><sec><title>Conclusion</title><p><italic>H. pylori</italic> eradication for GC patients who underwent distal gastrectomy did not compromise long-term survival after surgery.</p></sec></abstract><kwd-group><kwd><italic>Helicobacter pylori</italic></kwd><kwd>Stomach Neoplasms</kwd><kwd>Gastrectomy</kwd><kwd>Survival</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Guidelines recommend <italic>Helicobacter pylori</italic> eradication in patients who undergo distal gastrectomy for treatment of gastric neoplasia [<xref rid="b1-crt-2015-264" ref-type="bibr">1</xref>]. Despite these recommendations, several studies have reported poor long-term outcomes in patients negative for <italic>H. pylori</italic> infection after gastrectomy [<xref rid="b2-crt-2015-264" ref-type="bibr">2</xref>-<xref rid="b4-crt-2015-264" ref-type="bibr">4</xref>]. In these studies, negative <italic>H. pylori</italic> status was an independent poor prognostic factor for overall survival (OS) [<xref rid="b2-crt-2015-264" ref-type="bibr">2</xref>,<xref rid="b4-crt-2015-264" ref-type="bibr">4</xref>], gastric cancer-specific survival [<xref rid="b3-crt-2015-264" ref-type="bibr">3</xref>], and relapse-free survival [<xref rid="b2-crt-2015-264" ref-type="bibr">2</xref>]. In addition, gastric cancers in patients without <italic>H. pylori</italic> infection had poorer clinicopathological features compared with those in patients with <italic>H. pylori</italic> infection, including larger tumor size, more advanced stage, and more frequent lymph node or distant metastases [<xref rid="b3-crt-2015-264" ref-type="bibr">3</xref>-<xref rid="b7-crt-2015-264" ref-type="bibr">7</xref>].</p><p>However, <italic>H. pylori</italic> eradication or <italic>H. pylori</italic>&#x02013;negative status after endoscopic resection for gastric cancer has been associated with a reduced risk for development of metachronous cancers in the remnant stomach [<xref rid="b8-crt-2015-264" ref-type="bibr">8</xref>,<xref rid="b9-crt-2015-264" ref-type="bibr">9</xref>]. In addition, <italic>H. pylori</italic> eradication leads to improvement of premalignant conditions, such as mucosal atrophy and intestinal metaplasia, in the remnant stomach after gastrectomy [<xref rid="b10-crt-2015-264" ref-type="bibr">10</xref>,<xref rid="b11-crt-2015-264" ref-type="bibr">11</xref>]. Therefore, <italic>H. pylori</italic> eradication may have beneficial effects, including the potential prevention of metachronous cancers after gastrectomy.</p><p>In a previous double-blind randomized controlled study, we reported that <italic>H. pylori</italic> eradication improved the histological changes of the remnant stomach mucosa, such as atrophy and intestinal metaplasia, after subtotal gastrectomy for gastric cancer [<xref rid="b10-crt-2015-264" ref-type="bibr">10</xref>]. In the current study, we evaluated long-term outcomes, including survival and cancer recurrence, to determine whether <italic>H. pylori</italic> eradication has a detrimental effect on long-term survival after distal gastrectomy for gastric cancer.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>1. Study population</title><p>We observed patients enrolled in a previous double-blind randomized controlled trial evaluating the effects of <italic>H. pylori</italic> eradication on mucosal atrophy and intestinal metaplasia in the remnant stomach after distal gastrectomy [<xref rid="b10-crt-2015-264" ref-type="bibr">10</xref>]. Detailed methods were described previously. In brief, newly diagnosed gastric cancer patients aged 18 to 70 years were recruited and screened for eligibility at the National Cancer Center, Korea, between August 2003 and May 2006. Eligibility criteria were as follows: distal gastric adenocarcinoma of clinical stage IA, IB, II, or IIIA according to the 6th edition of the International Union Against Cancer/American Joint Committee on Cancer TNM classification system [<xref rid="b12-crt-2015-264" ref-type="bibr">12</xref>], and positive tests for <italic>H. pylori</italic> infection. Informed consent was obtained from all participants. The Institutional Review Board of the National Cancer Center, Korea, approved the study protocol (NCCCTS03-063) and the original trial was registered with ClinicalTrials.gov (NCT01002443) [<xref rid="b10-crt-2015-264" ref-type="bibr">10</xref>].</p></sec><sec><title>2. <italic>H. pylori</italic> status evaluation</title><p>Both the rapid urea test (RUT) and histology before distal gastrectomy were used for assessment of <italic>H. pylori</italic> infection. On the initial esophagogastroduodenoscopy (EGD), six biopsy specimens were taken from the lesser curvature of the antrum and the lesser and greater curvatures of the corpus for evaluation of <italic>H. pylori</italic> status, mucosal atrophy, and intestinal metaplasia. The collected biopsy specimens were immediately fixed in neutral-buffered 10% formalin, embedded in paraffin blocks, and stained with hematoxylin-eosin and Wright-Giemsa for histological evaluation. A single pathologist (M.-C.K.) performed pathological evaluation. One additional biopsy specimen was taken from the greater curvature of the corpus for RUT (Proton Dry, Medical Instruments Corporation, Solothurn, Switzerland). Patients confirmed as <italic>H. pylori</italic> infection by both a positive RUT and histological evaluation were enrolled in the study.</p></sec><sec><title>3. Randomization and surgery</title><p>Eligible patients were randomly assigned to the treatment group or the placebo group by computer-generated random number. All investigators and patients were blinded to the randomization results throughout the trial. The treatment group received proton pump inhibitor (PPI)&#x02013;based standard triple therapy, consisting of rabeprazole 10 mg, clarithromycin 500 mg, and amoxicillin 1,000 mg twice daily for 7 days. The placebo group received the same schedule of rabeprazole 10 mg but received a placebo rather than clarithromycin and amoxicillin. These treatments were administered before distal gastrectomy. Then, all patients underwent an open or laparoscopic distal gastrectomy with D1+ or D2 lymph node dissection [<xref rid="b13-crt-2015-264" ref-type="bibr">13</xref>]. The reconstruction methods were Billroth I (gastroduodenostomy) or II (gastrojejunostomy).</p></sec><sec><title>4. Follow-up <italic>H. pylori</italic> status</title><p>Follow-up EGDs with biopsy, RUT, and urea breath test (UBT) were performed at 3 months after distal gastrectomy for assessment of <italic>H. pylori</italic> status. The biopsy specimens were taken from the lesser and greater curvatures of the corpus, but not the antrum. At the follow-up examination, <italic>H. pylori</italic> was considered negative if all three tests were negative.</p></sec><sec><title>5. Statistical analysis</title><p>The calculation of study sample size was described in detail previously [<xref rid="b10-crt-2015-264" ref-type="bibr">10</xref>]. In the current study, outcomes were OS, gastric cancer-specific death, and gastric cancer recurrence. OS and gastric cancer-specific survival were determined from the time of distal gastrectomy to death; OS included deaths from any cause, but gastric cancer-specific death included only death from gastric cancer. Gastric cancer recurrence included metachronous cancer in the remnant stomach, lymph node metastasis, and distant organ metastasis occurring after gastrectomy for distal gastrectomy.</p><p>Continuous variables were compared using the Mann-Whitney U test and categorical variables were compared using the chi-square test or Fisher exact test. Follow-up data on deaths and recurrences were obtained until December 2014. The Kaplan-Meier method was used for construction of survival curves, and comparisons were performed using the log-rank test. Comparisons of gastric cancer-specific death and gastric cancer recurrence rates were performed using Gray&#x02019;s test because of the possible competing risk of death without recurrence. A multivariate Cox proportional hazards model analysis was performed for overall mortality, and a multivariate Fine-Gray regression model analysis was performed for cancer recurrence with competing risks. In model 1, multivariate analyses were performed according to the allocated groups, and in model 2, analyses were performed according to the <italic>H. pylori</italic> status at 3 months after gastrectomy. Covariates for multivariate analyses were age, sex, and variables having a p-value less than 0.1 in univariate analyses. Analyses were performed using STATA ver. 12.1 (Stata Corp., College Station, TX), except for the Gray&#x02019;s test, which was analyzed using SAS ver. 9.3 (SAS Inc., Cary, NC). A p-value less than 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Of the 190 randomized patients, 169 patients who received treatment or placebo were included in the analyses; 87 in the treatment group and 82 in the placebo group. At 3 months after distal gastrectomy, <italic>H. pylori</italic> infection status was evaluated using UBT, histology, and RUT in 167 patients; 67 patients in the treatment group (81.7%, 67/86 patients) and 15 patients in the placebo group (18.3%, 15/81 patients) were negative for <italic>H. pylori</italic> infection (<xref rid="f1-crt-2015-264" ref-type="fig">Fig. 1</xref>). These patients were included in the analyses according to the <italic>H. pylori</italic> status at 3 months after distal gastrectomy.</p><p>Baseline characteristics of the 169 allocated patients and 167 patients who underwent follow-up <italic>H. pylori</italic> tests at 3 months after gastrectomy are summarized in <xref rid="t1-crt-2015-264" ref-type="table">Table 1</xref>. Median age was 57 years (interquartile range [IQR], 48 to 64 years) and the proportion of male patients was 69.2% (117 patients). There were no differences in age, sex, smoking, alcohol drinking, surgical methods, reconstruction methods, pathologic stage, and histology between the treatment and placebo groups. Comparisons according to <italic>H. pylori</italic> status at 3 months after gastrectomy showed no significant differences in baseline characteristics except for the final cancer stage after surgery; a higher proportion of patients with <italic>H. pylori</italic>positive status had stage I cancer compared to those with <italic>H. pylori</italic>-negative status (80.0% vs. 72.0%, respectively; p=0.033).</p><sec><title>1. Comparisons of long-term survival rates after distal gastrectomy</title><p>During a median follow-up period of 9.4 years (IQR, 9.0 to 10.2 years; range, 0.7 to 11.3 years), 26 patients died: 14 in the treatment group and 12 in the placebo group. The 5-year OS rates were 98.9% in the treatment group and 91.5% in the placebo group, and results of Kaplan-Meier analysis showed no significant difference between groups (p=0.957 by log-rank test) (<xref rid="f2-crt-2015-264" ref-type="fig">Fig. 2A</xref>). Overall, 13 patients had gastric cancer recurrence (6 [6.9%] in the treatment group and 7 [8.5%] in the placebo group). Of these, metachronous cancers occurred in 4 patients (3 patients in the treatment group and 1 patient in the placebo group), and the metachronous cancer rates were not different between the treatment group and the placebo group (3.5% vs. 1.5%, p=0.341). One patient died of gastric cancer metastasis at 5 months after total gastrectomy for metachronous cancer, while, the remaining nine patients had lymph node or other organ metastases (3 patients in the treatment group and 6 patients in the placebo group). Of the patients with gastric cancer recurrence, 10 patients died because of gastric cancer recurrence (4 patients in the treatment group and 6 patients in the placebo group). The 5-year incidence rates of gastric cancer recurrence were 4.6% in the treatment group and 8.5% in the placebo group, and Gray&#x02019;s test showed no statistical significance (p=0.652) (<xref rid="f2-crt-2015-264" ref-type="fig">Fig. 2B</xref>). No difference in the cumulative incidences of gastric cancer-specific death were observed between the treatment and placebo groups (5-year cumulative incidence rate, 1.1% vs. 6.1%, respectively; p=0.422 by Gray&#x02019;s test) (<xref rid="f2-crt-2015-264" ref-type="fig">Fig. 2C</xref>).</p><p>At 3 months after gastrectomy, 82 patients had negative <italic>H. pylori</italic> status and 85 had positive <italic>H. pylori</italic> status. After gastrectomy, OS did not differ between patients with negative <italic>H. pylori</italic> status and those with positive <italic>H. pylori</italic> status (5-year OS rates, 96.3% vs. 94.1%, respectively; p=0.997 by log-rank test) (<xref rid="f3-crt-2015-264" ref-type="fig">Fig. 3A</xref>). In addition, no statistical differences in gastric cancer recurrence (5-year cumulative incidence rates, 6.1% for negative status vs. 7.1% for positive status; p=0.897 by Gray&#x02019;s test) (<xref rid="f3-crt-2015-264" ref-type="fig">Fig. 3B</xref>) and gastric cancer-specific death (5-year cumulative incidence rates, 3.7% for negative status vs. 3.5% for positive status; p=0.792 by Gray&#x02019;s test) (<xref rid="f3-crt-2015-264" ref-type="fig">Fig. 3C</xref>) were observed between patients with and without <italic>H. pylori</italic> at 3 months after distal gastrectomy.</p></sec><sec><title>2. Univariate and multivariate analyses for overall mortality and cancer recurrence</title><p>In univariate analyses, overall mortality after distal gastrectomy was not affected by <italic>H. pylori</italic> treatment allocation (crude hazard ratio [cHR] for <italic>H. pylori</italic> treatment, 1.02; p=0.957) or positive <italic>H. pylori</italic> status at 3 months after distal gastrectomy (cHR for <italic>H. pylori</italic>&#x02013;positive, 1.00; p=0.997). Male sex, Billroth II anastomosis after distal gastrectomy, and stage &#x02265; IIIa were significant factors associated with overall mortality. In model 1, multivariate analysis according to <italic>H. pylori</italic> treatment allocation showed that age (adjusted HR [aHR], 1.06; p=0.017), male sex (aHR, 8.38; p=0.005), and advanced stage &#x02265; IIIa (aHR, 9.18; p &#x0003c; 0.001) were independent risk factors for overall mortality. <italic>H. pylori</italic> treatment was not a significant factor for overall mortality (aHR for treatment group, 0.75; p=0.495). In model 2, positive <italic>H. pylori</italic> status at 3 months after gastrectomy did not show significant association with overall mortality (aHR, 1.16; p=0.715), whereas age, male sex, and advanced stage &#x02265; IIIa were independent risk factors for overall mortality (<xref rid="t2-crt-2015-264" ref-type="table">Table 2</xref>).</p><p>For cancer recurrence, neither <italic>H. pylori</italic> treatment (cHR, 0.78; p=0.649) nor positive <italic>H. pylori</italic> status after gastrectomy (cHR, 1.13; p=0.821) were significant factors in univariate analyses. Multivariate Fine-Gray regression analyses showed that only the advanced stage &#x02265; IIIa was a significant risk factor in both model 1 and 2. In these analyses, <italic>H. pylori</italic> treatment (aHR, 0.60; p=0.431) and positive <italic>H. pylori</italic> status at 3 months after distal gastrectomy (aHR, 1.05; p=0.921) did not affect cancer recurrence (<xref rid="t3-crt-2015-264" ref-type="table">Table 3</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In the current long-term follow-up study of a double-blind randomized trial, <italic>H. pylori</italic> treatment and <italic>H. pylori</italic> infection status did not affect long-term outcomes after distal gastrectomy, including OS, gastric cancer recurrence, and gastric cancer-specific death. Several studies have reported an association of <italic>H. pylori</italic> infection status with long-term outcomes after gastrectomy. One prospective [<xref rid="b2-crt-2015-264" ref-type="bibr">2</xref>] and two retrospective studies [<xref rid="b3-crt-2015-264" ref-type="bibr">3</xref>,<xref rid="b4-crt-2015-264" ref-type="bibr">4</xref>] reported that negative <italic>H. pylori</italic> status is a poor prognostic factor for long-term outcomes after gastrectomy. Meimarakis et al. [<xref rid="b2-crt-2015-264" ref-type="bibr">2</xref>] reported that negative <italic>H. pylori</italic> status after surgery is an independent risk factor associated with poor OS and recurrence-free survival, and Marrelli et al. [<xref rid="b3-crt-2015-264" ref-type="bibr">3</xref>] reported that negative <italic>H. pylori</italic> status is a poor prognostic factor for OS. Kang et al. [<xref rid="b4-crt-2015-264" ref-type="bibr">4</xref>] reported an association of negative <italic>H. pylori</italic> status with poor OS in patients who received adjuvant chemotherapy for locally advanced gastric cancer (stage IB to IV) after gastrectomy. In these studies, the negative <italic>H. pylori</italic> status group likely included heterogeneous patients who were initially negative for <italic>H. pylori</italic> infection or those whose <italic>H. pylori</italic> infection disappeared because of the advances of atrophy or <italic>H. pylori</italic> treatment. It appears that negative <italic>H. pylori</italic> status due to any cause may affect long-term survival after gastrectomy. However, our findings suggest that negative <italic>H. pylori</italic> status resulting from <italic>H. pylori</italic> treatment does not affect long-term outcomes after distal gastrectomy.</p><p>In comparison with <italic>H. pylori</italic>&#x02013;positive gastric cancer,<italic>H. pylori</italic>&#x02013;negative gastric cancer had the following clinical characteristics: prevalence in younger patients, tumor location in the upper-third portion of the stomach, and more frequent diffuse-type histology [<xref rid="b5-crt-2015-264" ref-type="bibr">5</xref>,<xref rid="b7-crt-2015-264" ref-type="bibr">7</xref>,<xref rid="b14-crt-2015-264" ref-type="bibr">14</xref>]. In addition, <italic>H. pylori</italic>&#x02013;negative patients had higher advanced cancer stage [<xref rid="b5-crt-2015-264" ref-type="bibr">5</xref>] or distant metastasis [<xref rid="b7-crt-2015-264" ref-type="bibr">7</xref>], suggesting poor clinical outcomes. In the aforementioned studies that reported poorer long-term survival rates after gastrectomy in <italic>H. pylori</italic>&#x02013;negative gastric cancer patients, baseline clinical characteristics were also different between <italic>H. pylori</italic>&#x02013;negative and &#x02013;positive groups. <italic>H. pylori</italic>&#x02013;negative patients had a significantly higher proportion of tumors located proximally [<xref rid="b2-crt-2015-264" ref-type="bibr">2</xref>,<xref rid="b3-crt-2015-264" ref-type="bibr">3</xref>], and more of these patients underwent total gastrectomy [<xref rid="b2-crt-2015-264" ref-type="bibr">2</xref>]. <italic>H. pylori</italic>&#x02013;negative patients had more advanced tumor stage [<xref rid="b3-crt-2015-264" ref-type="bibr">3</xref>,<xref rid="b4-crt-2015-264" ref-type="bibr">4</xref>] and larger tumor size [<xref rid="b4-crt-2015-264" ref-type="bibr">4</xref>] than <italic>H. pylori</italic>&#x02013;positive patients. These findings suggest that <italic>H. pylori</italic>&#x02013;negative gastric cancer may be intrinsically associated with poor clinicopathological features. In a recent study, gastric cancers were classified according to molecular subtype [<xref rid="b15-crt-2015-264" ref-type="bibr">15</xref>]. <italic>H. pylori</italic> infection is also related to some of the molecular changes associated with gastric carcinogenesis, including genetic instability and epigenetic changes in oncogenes or tumor suppressor genes [<xref rid="b16-crt-2015-264" ref-type="bibr">16</xref>]. Different molecular changes are likely in <italic>H. pylori</italic>&#x02013;negative gastric cancer compared with <italic>H. pylori</italic>&#x02013;positive gastric can cer, which may be associated with poor long-term outcomes.</p><p>A possible mechanism for the prognostic role of <italic>H. pylori</italic> infection after gastrectomy is that <italic>H. pylori</italic>&#x02013;induced tumor-specific immune responses may be down-regulated in <italic>H. pylori</italic>&#x02013;negative gastric cancer patients, possibly influencing long-term outcomes [<xref rid="b2-crt-2015-264" ref-type="bibr">2</xref>]. However, this mechanism has not been proven in clinical studies, and other factors could affect the outcomes for these patients. In the current study, long-term outcomes were not affected by <italic>H. pylori</italic> status after gastrectomy; however, age, male sex, and advanced stage were independent risk factors for overall mortality. Advanced stage was also a significant risk factor for cancer recurrence. In addition, Hobsley et al. [<xref rid="b17-crt-2015-264" ref-type="bibr">17</xref>] commented that negative <italic>H. pylori</italic> status might simply be associated with more advanced tumor progression rather than related to poor prognosis, consistent with our findings.</p><p>In our previous study, most <italic>H. pylori</italic>&#x02013;negative gastric cancers occurred in patients with past <italic>H. pylori</italic> infection, and patients who were truly negative for <italic>H. pylori</italic> infection were rare, occurring at a rate of 2.3% [<xref rid="b7-crt-2015-264" ref-type="bibr">7</xref>]. Compared with true <italic>H. pylori</italic>&#x02013;negative gastric cancer patients, gastric cancer patients with past <italic>H. pylori</italic> infection were older and predominantly male, and had a higher proportion of intestinal-type histology and a lower distant metastasis rate [<xref rid="b7-crt-2015-264" ref-type="bibr">7</xref>]. In the current study, <italic>H. pylori</italic>&#x02013;negative patients were those with past <italic>H. pylori</italic> infection that was eradicated upon treatment with PPI-based standard triple therapy. Clinical characteristics of patients in the <italic>H. pylori</italic>&#x02013;negative group may be different from those of true <italic>H. pylori</italic>&#x02013;negative gastric cancer patients, and in this instance, long-term outcomes after distal gastrectomy were not affected by <italic>H. pylori</italic> treatment.</p><p>Because of the possible roles of <italic>H. pylori</italic> infection in carcinogenesis in the remnant stomach mucosa after treatment of gastric cancer [<xref rid="b18-crt-2015-264" ref-type="bibr">18</xref>], guidelines recommend <italic>H. pylori</italic> eradication to prevent development of new cancers in patients who undergo distal gastrectomy [<xref rid="b1-crt-2015-264" ref-type="bibr">1</xref>]. In patients undergoing gastrectomy, <italic>H. pylori</italic> infection may induce chronic and active gastritis, and is associated with increased corpus mucosal cell proliferation in the remnant stomach [<xref rid="b18-crt-2015-264" ref-type="bibr">18</xref>-<xref rid="b20-crt-2015-264" ref-type="bibr">20</xref>]. By contrast, <italic>H. pylori</italic>&#x02013;negative status is associated with a low risk of mucosal atrophy and intestinal metaplasia in the remnant stomach after gastrectomy [<xref rid="b10-crt-2015-264" ref-type="bibr">10</xref>,<xref rid="b11-crt-2015-264" ref-type="bibr">11</xref>,<xref rid="b18-crt-2015-264" ref-type="bibr">18</xref>,<xref rid="b21-crt-2015-264" ref-type="bibr">21</xref>]. In addition, in early gastric cancer patients undergoing endoscopic resection, a previous randomized controlled study reported that <italic>H. pylori</italic> treatment reduces the incidence of metachronous cancers [<xref rid="b8-crt-2015-264" ref-type="bibr">8</xref>], and a recent meta-analysis also reported significantly reduced incidences of metachronous gastric neoplasia for <italic>H. pylori</italic>&#x02013;eradicated patients [<xref rid="b22-crt-2015-264" ref-type="bibr">22</xref>]. However, in the current study metachronous cancer rates were not different according to <italic>H. pylori</italic> treatment or according to <italic>H. pylori</italic> status. This may be because all of the included patients underwent gastric resection of the distal portion of the stomach, which is the common site for synchronous [<xref rid="b23-crt-2015-264" ref-type="bibr">23</xref>] or metachronous cancer [<xref rid="b24-crt-2015-264" ref-type="bibr">24</xref>]. Studies with a proper design and adequate sample size are needed to evaluate the question of whether <italic>H. pylori</italic> eradication may be a preventive strategy for development of metachronous gastric cancer after distal gastrectomy.</p><p>The main strength of this study was that it collected long-term follow-up data from gastric cancer patients who underwent distal gastrectomy in a prospective double-blind randomized controlled trial. Thus, we performed intention-to-treat analysis to determine whether <italic>H. pylori</italic> treatment affects long-term outcomes after distal gastrectomy in gastric cancer patients.</p><p>However, the current study had several limitations. First, the study sample size may not be large enough to evaluate the association between <italic>H. pylori</italic> infection status and long-term outcomes, because the sample size originally calculated was for the first study, which assessed the histological improvement of the lessor curvature of the corpus after distal gastrectomy [<xref rid="b10-crt-2015-264" ref-type="bibr">10</xref>]. Thus, an additional study including more enrolled patients is needed to provide adequate power. Second, the findings of the current study may not be applicable to areas where the prevalence of <italic>H. pylori</italic> infection and the incidence of gastric cancer are low. Third, spontaneous clearance of <italic>H. pylori</italic> infection during follow-up after gastrectomy was reported in the previous study [<xref rid="b25-crt-2015-264" ref-type="bibr">25</xref>]. Therefore, some <italic>H. pylori</italic>-positive patients in the current study might have spontaneous negative conversion of <italic>H. pylori</italic> infection after distal gastrectomy, and long-term outcomes might be affected by the spontaneous clearance of <italic>H. pylori</italic> infection. Finally, clinicopathological characteristics according to the virulence factors of <italic>H. pylori</italic> strains were not evaluated in the current study.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In conclusion, <italic>H. pylori</italic> eradication for gastric cancer patients who undergo distal gastrectomy appears to have no effect on long-term survival and cancer recurrence rates after surgery. Thus, <italic>H. pylori</italic> eradication in gastric cancer patients after distal gastrectomy may be performed without concern for compromising long-term survival.</p></sec></body><back><fn-group><fn fn-type="conflict"><p>Conflict of interest relevant to this article was not reported.</p></fn></fn-group><ack><p>This work was supported by grant 1310280 from the National Cancer Center, Korea.</p></ack><ref-list><title>References</title><ref id="b1-crt-2015-264"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>IJ</given-names></name></person-group><article-title>Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer</article-title><source>Korean J Intern Med</source><year>2013</year><volume>28</volume><fpage>525</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">24009446</pub-id></element-citation></ref><ref id="b2-crt-2015-264"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meimarakis</surname><given-names>G</given-names></name><name><surname>Winter</surname><given-names>H</given-names></name><name><surname>Assmann</surname><given-names>I</given-names></name><name><surname>Kopp</surname><given-names>R</given-names></name><name><surname>Lehn</surname><given-names>N</given-names></name><name><surname>Kist</surname><given-names>M</given-names></name><etal/></person-group><article-title>Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study</article-title><source>Lancet Oncol</source><year>2006</year><volume>7</volume><fpage>211</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">16510330</pub-id></element-citation></ref><ref id="b3-crt-2015-264"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrelli</surname><given-names>D</given-names></name><name><surname>Pedrazzani</surname><given-names>C</given-names></name><name><surname>Berardi</surname><given-names>A</given-names></name><name><surname>Corso</surname><given-names>G</given-names></name><name><surname>Neri</surname><given-names>A</given-names></name><name><surname>Garosi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer</article-title><source>Cancer</source><year>2009</year><volume>115</volume><fpage>2071</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">19280589</pub-id></element-citation></ref><ref id="b4-crt-2015-264"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SY</given-names></name><name><surname>Han</surname><given-names>JH</given-names></name><name><surname>Ahn</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>Jeong</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection</article-title><source>Int J Cancer</source><year>2012</year><volume>130</volume><fpage>948</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">21425257</pub-id></element-citation></ref><ref id="b5-crt-2015-264"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Shin</surname><given-names>CM</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics</article-title><source>Helicobacter</source><year>2011</year><volume>16</volume><fpage>382</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21923684</pub-id></element-citation></ref><ref id="b6-crt-2015-264"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>HB</given-names></name><name><surname>Zhang</surname><given-names>LY</given-names></name><name><surname>Keshari</surname><given-names>RP</given-names></name><name><surname>Wang</surname><given-names>GQ</given-names></name><name><surname>Zhou</surname><given-names>ZW</given-names></name><name><surname>Xu</surname><given-names>DZ</given-names></name><etal/></person-group><article-title>Relationship between H. pylori infection and clinicopathological features and prognosis of gastric cancer</article-title><source>BMC Cancer</source><year>2010</year><volume>10</volume><fpage>374</fpage><pub-id pub-id-type="pmid">20637122</pub-id></element-citation></ref><ref id="b7-crt-2015-264"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>HW</given-names></name><name><surname>Choi</surname><given-names>IJ</given-names></name><name><surname>Cho</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>CG</given-names></name><name><surname>Kook</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Characteristics of gastric cancer according to Helicobacter pylori infection status</article-title><source>J Gastroenterol Hepatol</source><year>2014</year><volume>29</volume><fpage>1671</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24730518</pub-id></element-citation></ref><ref id="b8-crt-2015-264"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukase</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Uemura</surname><given-names>N</given-names></name><name><surname>Okamoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>392</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18675689</pub-id></element-citation></ref><ref id="b9-crt-2015-264"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YI</given-names></name><name><surname>Choi</surname><given-names>IJ</given-names></name><name><surname>Kook</surname><given-names>MC</given-names></name><name><surname>Cho</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>CG</given-names></name><etal/></person-group><article-title>The association between Helicobacter pylori status and incidence of metachronous gastric cancer after endoscopic resection of early gastric cancer</article-title><source>Helicobacter</source><year>2014</year><volume>19</volume><fpage>194</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">24612125</pub-id></element-citation></ref><ref id="b10-crt-2015-264"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>SJ</given-names></name><name><surname>Choi</surname><given-names>IJ</given-names></name><name><surname>Kook</surname><given-names>MC</given-names></name><name><surname>Yoon</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer</article-title><source>Aliment Pharmacol Ther</source><year>2013</year><volume>38</volume><fpage>477</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">23822578</pub-id></element-citation></ref><ref id="b11-crt-2015-264"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>JJ</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Kang</surname><given-names>KK</given-names></name><name><surname>Lee</surname><given-names>AR</given-names></name><name><surname>Yoon</surname><given-names>H</given-names></name><name><surname>Shin</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Eradication rate and histological changes after Helicobacter pylori eradication treatment in gastric cancer patients following subtotal gastrectomy</article-title><source>World J Gastroenterol</source><year>2015</year><volume>21</volume><fpage>3936</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">25852279</pub-id></element-citation></ref><ref id="b12-crt-2015-264"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sobin</surname><given-names>LH</given-names></name><name><surname>Wittekind</surname><given-names>C</given-names></name></person-group><source>TNM classification of malignant tumours</source><edition>6th ed</edition><publisher-loc>New York</publisher-loc><publisher-name>Wiley-Liss</publisher-name><year>2002</year></element-citation></ref><ref id="b13-crt-2015-264"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Japanese Gastric Cancer Association</collab></person-group><article-title>Japanese gastric cancer treatment guidelines 2010 (ver. 3)</article-title><source>Gastric Cancer</source><year>2011</year><volume>14</volume><fpage>113</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">21573742</pub-id></element-citation></ref><ref id="b14-crt-2015-264"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Takata</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Yoshihara</surname><given-names>M</given-names></name><name><surname>Chayama</surname><given-names>K</given-names></name></person-group><article-title>Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese</article-title><source>Helicobacter</source><year>2011</year><volume>16</volume><fpage>415</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22059391</pub-id></element-citation></ref><ref id="b15-crt-2015-264"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><article-title>Comprehensive molecular characterization of gastric adenocarcinoma</article-title><source>Nature</source><year>2014</year><volume>513</volume><fpage>202</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">25079317</pub-id></element-citation></ref><ref id="b16-crt-2015-264"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanada</surname><given-names>K</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name></person-group><article-title>Helicobacter pylori and the molecular pathogenesis of intestinal-type gastric carcinoma</article-title><source>Expert Rev Anticancer Ther</source><year>2014</year><volume>14</volume><fpage>947</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">24802804</pub-id></element-citation></ref><ref id="b17-crt-2015-264"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobsley</surname><given-names>M</given-names></name><name><surname>Tovey</surname><given-names>FI</given-names></name><name><surname>Holton</surname><given-names>J</given-names></name></person-group><article-title>Helicobacter pylori and gastric cancer: neither friend nor foe</article-title><source>Gastroenterology</source><year>2007</year><volume>132</volume><fpage>2076</fpage><pub-id pub-id-type="pmid">17484909</pub-id></element-citation></ref><ref id="b18-crt-2015-264"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YS</given-names></name><name><surname>Chen</surname><given-names>MJ</given-names></name><name><surname>Shih</surname><given-names>SC</given-names></name><name><surname>Bair</surname><given-names>MJ</given-names></name><name><surname>Fang</surname><given-names>CJ</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name></person-group><article-title>Management of Helicobacter pylori infection after gastric surgery</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>5274</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">24833857</pub-id></element-citation></ref><ref id="b19-crt-2015-264"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Tokunaga</surname><given-names>A</given-names></name><name><surname>Tajiri</surname><given-names>T</given-names></name><name><surname>Masuda</surname><given-names>G</given-names></name><name><surname>Okuda</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>I</given-names></name><etal/></person-group><article-title>Inflammation of the gastric remnant after gastrectomy: mucosal erythema is associated with bile reflux and inflammatory cellular infiltration is associated with Helicobacter pylori infection</article-title><source>J Gastroenterol</source><year>2004</year><volume>39</volume><fpage>520</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15235868</pub-id></element-citation></ref><ref id="b20-crt-2015-264"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>DA</given-names></name><name><surname>Mapstone</surname><given-names>NP</given-names></name><name><surname>Clarke</surname><given-names>AM</given-names></name><name><surname>Jackson</surname><given-names>P</given-names></name><name><surname>Dixon</surname><given-names>MF</given-names></name><name><surname>Quirke</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cell proliferation in the gastric corpus in Helicobacter pylori associated gastritis and after gastric resection</article-title><source>Gut</source><year>1995</year><volume>36</volume><fpage>351</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">7698691</pub-id></element-citation></ref><ref id="b21-crt-2015-264"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakakibara</surname><given-names>M</given-names></name><name><surname>Ando</surname><given-names>T</given-names></name><name><surname>Ishiguro</surname><given-names>K</given-names></name><name><surname>Maeda</surname><given-names>O</given-names></name><name><surname>Watanabe</surname><given-names>O</given-names></name><name><surname>Hirayama</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Usefulness of Helicobacter pylori eradication for precancerous lesions of the gastric remnant</article-title><source>J Gastroenterol Hepatol</source><year>2014</year><volume>29 Suppl 4</volume><fpage>60</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">25521735</pub-id></element-citation></ref><ref id="b22-crt-2015-264"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Chung</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>JC</given-names></name><name><surname>Shin</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: a meta-analysis</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><elocation-id/></element-citation></ref><ref id="b23-crt-2015-264"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eom</surname><given-names>BW</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>IJ</given-names></name><name><surname>Kook</surname><given-names>MC</given-names></name><name><surname>Nam</surname><given-names>BH</given-names></name><name><surname>Ryu</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Pretreatment risk factors for multiple gastric cancer and missed lesions</article-title><source>J Surg Oncol</source><year>2012</year><volume>105</volume><fpage>813</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22006627</pub-id></element-citation></ref><ref id="b24-crt-2015-264"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasu</surname><given-names>J</given-names></name><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Endo</surname><given-names>H</given-names></name><name><surname>Nishina</surname><given-names>T</given-names></name><name><surname>Hirasaki</surname><given-names>S</given-names></name><name><surname>Hyodo</surname><given-names>I</given-names></name></person-group><article-title>Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection</article-title><source>Endoscopy</source><year>2005</year><volume>37</volume><fpage>990</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">16189772</pub-id></element-citation></ref><ref id="b25-crt-2015-264"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bair</surname><given-names>MJ</given-names></name><name><surname>Wu</surname><given-names>MS</given-names></name><name><surname>Chang</surname><given-names>WH</given-names></name><name><surname>Shih</surname><given-names>SC</given-names></name><name><surname>Wang</surname><given-names>TE</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Spontaneous clearance of Helicobacter pylori colonization in patients with partial gastrectomy: correlates with operative procedures and duration after operation</article-title><source>J Formos Med Assoc</source><year>2009</year><volume>108</volume><fpage>13</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19181603</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-crt-2015-264" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Study flowchart. EGD, esophagogastroduodenoscopy; <italic>H. pylori</italic>, <italic>Helicobacter pylori</italic>; RUT, rapid urease test; UBT, urea breath test.</p></caption><graphic xlink:href="crt-2015-264f1"/></fig><fig id="f2-crt-2015-264" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>Comparisons of long-term outcomes according to <italic>Helicobacter pylori</italic> treatment allocation. Overall survival (A), gastric cancer recurrence (B), and gastric cancer specific death curves (C).</p></caption><graphic xlink:href="crt-2015-264f2"/></fig><fig id="f3-crt-2015-264" orientation="portrait" position="float"><label>Fig. 3.</label><caption><p>Comparisons of long-term outcomes according to <italic>Helicobacter pylori</italic> status at 3 months after distal gastrectomy. Overall survival (A), gastric cancer recurrence (B), and gastric cancer specific death curves (C).</p></caption><graphic xlink:href="crt-2015-264f3"/></fig><table-wrap id="t1-crt-2015-264" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="middle" align="left" colspan="1">Characteristic</th><th colspan="3" valign="middle" align="center" rowspan="1">Initial allocation group<hr/></th><th colspan="3" valign="middle" align="center" rowspan="1"><italic>Helicobacter pylori</italic> status at 3 months after surgery<hr/></th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Placebo (n=82)</th><th valign="middle" align="center" rowspan="1" colspan="1">Treatment (n=87)</th><th valign="middle" align="center" rowspan="1" colspan="1">p-value</th><th valign="middle" align="center" rowspan="1" colspan="1">Negative (n=82)</th><th valign="middle" align="center" rowspan="1" colspan="1">Positive (n=85)</th><th valign="middle" align="center" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age, median (IQR, yr)</bold></td><td valign="middle" align="center" rowspan="1" colspan="1">56 (48-64)</td><td valign="middle" align="center" rowspan="1" colspan="1">58 (48-65)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.715</td><td valign="middle" align="center" rowspan="1" colspan="1">57 (46-64)</td><td valign="middle" align="center" rowspan="1" colspan="1">58 (48-64)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.743</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Sex</bold></td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="middle" align="center" rowspan="1" colspan="1">21 (25.6)</td><td valign="middle" align="center" rowspan="1" colspan="1">31 (35.6)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.158</td><td valign="middle" align="center" rowspan="1" colspan="1">25 (30.5)</td><td valign="middle" align="center" rowspan="1" colspan="1">27 (31.8)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.859</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Male</td><td valign="top" align="center" rowspan="1" colspan="1">61 (74.4)</td><td valign="middle" align="center" rowspan="1" colspan="1">56 (64.4)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">57 (69.5)</td><td valign="middle" align="center" rowspan="1" colspan="1">58 (68.2)</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Allocation group</bold></td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1">15 (18.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">66 (77.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Treatment</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">67 (81.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">19 (22.4)</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Alcohol drinking</bold></td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">35 (42.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">40 (46.0)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.667</td><td valign="middle" align="center" rowspan="1" colspan="1">38 (46.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">36 (42.4)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.604</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">47 (57.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">47 (54.0)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">44 (53.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">49 (57.7)</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Smoking</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">51 (62.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">46 (52.9)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.221</td><td valign="middle" align="center" rowspan="1" colspan="1">47 (57.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">49 (57.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.996</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">31 (37.8)</td><td valign="middle" align="center" rowspan="1" colspan="1">41 (47.1)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">35 (42.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">36 (42.4)</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Surgical method</bold></td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Laparoscopic</td><td valign="middle" align="center" rowspan="1" colspan="1">21 (25.6)</td><td valign="middle" align="center" rowspan="1" colspan="1">17 (19.5)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.345</td><td valign="middle" align="center" rowspan="1" colspan="1">15 (18.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">22 (25.9)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.238</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Open</td><td valign="middle" align="center" rowspan="1" colspan="1">61 (74.4)</td><td valign="middle" align="center" rowspan="1" colspan="1">70 (80.5)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">67 (81.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">63 (74.1)</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Reconstruction method</bold></td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Billroth I (gastroduodenostomy)</td><td valign="top" align="center" rowspan="1" colspan="1">63 (76.8)</td><td valign="middle" align="center" rowspan="1" colspan="1">59 (67.8)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.191</td><td valign="middle" align="center" rowspan="1" colspan="1">59 (72.0)</td><td valign="middle" align="center" rowspan="1" colspan="1">61 (71.8)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.979</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Billroth II (gastrojejunostomy)</td><td valign="middle" align="center" rowspan="1" colspan="1">19 (23.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">28 (32.2)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">23 (28.1)</td><td valign="middle" align="center" rowspan="1" colspan="1">24 (28.2)</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Histologic type</bold></td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Differentiated</td><td valign="middle" align="center" rowspan="1" colspan="1">48 (58.5)</td><td valign="middle" align="center" rowspan="1" colspan="1">51 (58.6)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.991</td><td valign="middle" align="center" rowspan="1" colspan="1">45 (54.9)</td><td valign="middle" align="center" rowspan="1" colspan="1">54 (63.5)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.255</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Undifferentiated</td><td valign="middle" align="center" rowspan="1" colspan="1">34 (41.5)</td><td valign="middle" align="center" rowspan="1" colspan="1">36 (41.4)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">37 (45.1)</td><td valign="middle" align="center" rowspan="1" colspan="1">31 (36.5)</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Final cancer stage after surgery</bold></td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Stage I</td><td valign="top" align="left" rowspan="1" colspan="1">66 (80.5)</td><td valign="middle" align="center" rowspan="1" colspan="1">63 (72.4)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.257</td><td valign="middle" align="center" rowspan="1" colspan="1">59 (72.0)</td><td valign="middle" align="center" rowspan="1" colspan="1">68 (80.0)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.033</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Stage II</td><td valign="middle" align="center" rowspan="1" colspan="1">10 (12.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">19 (21.8)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">20 (24.4)</td><td valign="middle" align="center" rowspan="1" colspan="1">9 (10.6)</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Stage IIIa or more</td><td valign="middle" align="center" rowspan="1" colspan="1">6 (7.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">5 (5.8)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">3 (3.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">8 (9.4)</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1-crt-2015-264"><p>Values are presented as number (%) unless otherwise indicated. IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-crt-2015-264" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Clinical and pathological factors associated with overall mortality</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="middle" align="left" colspan="1">Factor</th><th rowspan="2" valign="middle" align="center" colspan="1">No.</th><th colspan="2" valign="middle" align="center" rowspan="1">Univariate analysis<sup><xref rid="tfn3-crt-2015-264" ref-type="table-fn">a)</xref></sup><hr/></th><th colspan="2" valign="middle" align="center" rowspan="1">Multivariate analysis<sup><xref rid="tfn3-crt-2015-264" ref-type="table-fn">a)</xref></sup><hr/></th><th valign="middle" rowspan="1" colspan="1"/></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">cHR (95% CI) </th><th valign="middle" align="center" rowspan="1" colspan="1">p-value</th><th valign="middle" align="center" rowspan="1" colspan="1">aHR (95% CI)</th><th valign="middle" align="center" rowspan="1" colspan="1">p-value</th><th valign="middle" align="center" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Model 1. <italic>Helicobacter pylori</italic> allocation group</bold></td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Allocation group</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Placebo</td><td valign="middle" align="center" rowspan="1" colspan="1">82</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Treatment</td><td valign="top" align="center" rowspan="1" colspan="1">87</td><td valign="middle" align="center" rowspan="1" colspan="1">1.02 (0.47-2.21)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.957</td><td valign="middle" align="center" rowspan="1" colspan="1">0.75 (0.32-1.73)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.495</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Age (yr)</td><td valign="middle" align="center" rowspan="1" colspan="1">169</td><td valign="middle" align="center" rowspan="1" colspan="1">1.04 (0.99-1.08)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.119</td><td valign="middle" align="center" rowspan="1" colspan="1">1.06 (1.01-1.11)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.017</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Sex</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Female</td><td valign="middle" align="center" rowspan="1" colspan="1">52</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Male</td><td valign="middle" align="center" rowspan="1" colspan="1">117</td><td valign="middle" align="center" rowspan="1" colspan="1">6.11 (1.44-25.87)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.014</td><td valign="middle" align="center" rowspan="1" colspan="1">8.38 (1.87-37.42)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.005</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Alcohol drinking</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">75</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Yes</td><td valign="top" align="center" rowspan="1" colspan="1">94</td><td valign="middle" align="center" rowspan="1" colspan="1">1.23 (0.56-2.69)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.612</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Smoking</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">97</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">72</td><td valign="middle" align="center" rowspan="1" colspan="1">1.50 (0.69-3.24)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.305</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Surgical method</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Laparoscopic</td><td valign="middle" align="center" rowspan="1" colspan="1">38</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Open</td><td valign="middle" align="center" rowspan="1" colspan="1">131</td><td valign="middle" align="center" rowspan="1" colspan="1">3.77 (0.89-15.97)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.071</td><td valign="middle" align="center" rowspan="1" colspan="1">2.10 (0.47-9.43)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.335</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Reconstruction method</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Billroth I (gastroduodenostomy)</td><td valign="middle" align="center" rowspan="1" colspan="1">122</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Billroth II (gastrojejunostomy)</td><td valign="middle" align="center" rowspan="1" colspan="1">47</td><td valign="middle" align="center" rowspan="1" colspan="1">3.10 (1.42-6.74)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.004</td><td valign="middle" align="center" rowspan="1" colspan="1">1.56 (0.62-3.92)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.344</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Histologic type</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Differentiated</td><td valign="middle" align="center" rowspan="1" colspan="1">99</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Undifferentiated</td><td valign="middle" align="center" rowspan="1" colspan="1">70</td><td valign="middle" align="center" rowspan="1" colspan="1">0.68 (0.30-1.53)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.348</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Final cancer stage after surgery</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Stage I</td><td valign="middle" align="center" rowspan="1" colspan="1">129</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Stage II</td><td valign="middle" align="center" rowspan="1" colspan="1">29</td><td valign="middle" align="center" rowspan="1" colspan="1">1.63 (0.58-4.60)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.355</td><td valign="middle" align="center" rowspan="1" colspan="1">1.80 (0.59-5.46)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.298</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Stage IIIa or more</td><td valign="middle" align="center" rowspan="1" colspan="1">11</td><td valign="middle" align="center" rowspan="1" colspan="1">10.45 (4.31-25.38)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td><td valign="middle" align="center" rowspan="1" colspan="1">9.18 (3.25-25.97)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Model 2. <italic>H. pylori</italic> status at 3 months after surgery</bold><sup><xref rid="tfn4-crt-2015-264" ref-type="table-fn">b)</xref></sup></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;<italic>H. pylori</italic> status at 3 months after surgery</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Negative</td><td valign="middle" align="center" rowspan="1" colspan="1">82</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Positive</td><td valign="middle" align="center" rowspan="1" colspan="1">85</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00 (0.46-2.16)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.997</td><td valign="middle" align="center" rowspan="1" colspan="1">1.16 (0.52-2.57)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.715</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn2-crt-2015-264"><p>cHR, crude hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio.</p></fn><fn id="tfn3-crt-2015-264"><label>a)</label><p>Cox proportional hazards model was used for uni- and multivariate analyses,</p></fn><fn id="tfn4-crt-2015-264"><label>b)</label><p>Covariates for multivariate analysis in model 2 were age, sex, operation method, reconstruction method, and final cancer stage after surgery.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-crt-2015-264" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Clinical and pathological factors associated with gastric cancer recurrence</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="middle" align="left" colspan="1">Factor</th><th rowspan="2" valign="middle" align="center" colspan="1">No.</th><th colspan="2" valign="middle" align="center" rowspan="1">Univariate analysis<sup><xref rid="tfn6-crt-2015-264" ref-type="table-fn">a)</xref></sup><hr/></th><th colspan="2" valign="middle" align="center" rowspan="1">Multivariate analysis<sup><xref rid="tfn6-crt-2015-264" ref-type="table-fn">a)</xref></sup><hr/></th><th valign="middle" rowspan="1" colspan="1"/></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">cHR (95% CI)</th><th valign="middle" align="center" rowspan="1" colspan="1">p-value</th><th valign="middle" align="center" rowspan="1" colspan="1">aHR (95% CI)</th><th valign="middle" align="center" rowspan="1" colspan="1">p-value</th><th valign="middle" align="center" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Model 1. <italic>Helicobacter pylori</italic> allocation group</bold></td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Allocation group</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Placebo</td><td valign="middle" align="center" rowspan="1" colspan="1">82</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Treatment</td><td valign="top" align="center" rowspan="1" colspan="1">87</td><td valign="middle" align="center" rowspan="1" colspan="1">0.78 (0.26-2.29)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.649</td><td valign="middle" align="center" rowspan="1" colspan="1">0.60 (0.17-2.12)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.431</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Age (yr)</td><td valign="middle" align="center" rowspan="1" colspan="1">169</td><td valign="middle" align="center" rowspan="1" colspan="1">1.03 (0.96-1.10)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.359</td><td valign="middle" align="center" rowspan="1" colspan="1">1.06 (0.99-1.13)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.101</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Sex</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Female</td><td valign="middle" align="center" rowspan="1" colspan="1">52</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Male</td><td valign="middle" align="center" rowspan="1" colspan="1">117</td><td valign="middle" align="center" rowspan="1" colspan="1">2.50 (0.55-11.35)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.236</td><td valign="middle" align="center" rowspan="1" colspan="1">3.38 (0.56-20.54)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.185</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Alcohol drinking</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">75</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Yes</td><td valign="top" align="center" rowspan="1" colspan="1">94</td><td valign="middle" align="center" rowspan="1" colspan="1">1.31 (0.44-3.96)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.629</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Smoking</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">97</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">72</td><td valign="middle" align="center" rowspan="1" colspan="1">2.27 (0.75-6.85)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.145</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Surgical method</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Laparoscopic</td><td valign="middle" align="center" rowspan="1" colspan="1">38</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Open</td><td valign="middle" align="center" rowspan="1" colspan="1">131</td><td valign="middle" align="center" rowspan="1" colspan="1">1.63 (0.36-7.33)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.527</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Reconstruction method</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Billroth I (gastroduodenostomy)</td><td valign="middle" align="center" rowspan="1" colspan="1">122</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Billroth II (gastrojejunostomy)</td><td valign="middle" align="center" rowspan="1" colspan="1">47</td><td valign="middle" align="center" rowspan="1" colspan="1">3.22 (1.10-9.47)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.033</td><td valign="middle" align="center" rowspan="1" colspan="1">2.13 (0.48-9.40)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.319</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Histologic type</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Differentiated</td><td valign="middle" align="center" rowspan="1" colspan="1">99</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Undifferentiated</td><td valign="middle" align="center" rowspan="1" colspan="1">70</td><td valign="middle" align="center" rowspan="1" colspan="1">0.61 (0.19-2.00)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.416</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1">-</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Final cancer stage after surgery</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Stage I</td><td valign="middle" align="center" rowspan="1" colspan="1">129</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Stage II</td><td valign="middle" align="center" rowspan="1" colspan="1">29</td><td valign="middle" align="center" rowspan="1" colspan="1">2.30 (0.56-9.44)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.247</td><td valign="middle" align="center" rowspan="1" colspan="1">2.50 (0.44-14.03)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.299</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Stage IIIa or more</td><td valign="middle" align="center" rowspan="1" colspan="1">11</td><td valign="middle" align="center" rowspan="1" colspan="1">8.76 (2.58-29.70)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td><td valign="middle" align="center" rowspan="1" colspan="1">7.44 (1.55-35.58)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.012</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Model 2. <italic>H. pylori</italic> status at 3 months after surgery</bold><sup><xref rid="tfn7-crt-2015-264" ref-type="table-fn">b)</xref></sup></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;<italic>H. pylori</italic> status at 3 months after surgery</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Negative</td><td valign="middle" align="center" rowspan="1" colspan="1">82</td><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">1.00</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Positive</td><td valign="middle" align="center" rowspan="1" colspan="1">85</td><td valign="middle" align="center" rowspan="1" colspan="1">1.13 (0.38-3.35)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.821</td><td valign="middle" align="center" rowspan="1" colspan="1">1.05 (0.37-2.97)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.921</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn5-crt-2015-264"><p>cHR, crude hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio.</p></fn><fn id="tfn6-crt-2015-264"><label>a)</label><p>Fine-Gray regression model was used for uniand multivariate analyses,</p></fn><fn id="tfn7-crt-2015-264"><label>b)</label><p>Covariates for multivariate analysis in model 2 were age, sex, reconstruction method, and final cancer stage after surgery.</p></fn></table-wrap-foot></table-wrap></floats-group></article>